Novavax Inc
novavax.comNovavax (NASDAQ: NVAX) is a biotechnology company that develops and commercializes protein-based vaccines, with its primary product being a COVID-19 vaccine built on its recombinant nanoparticle technology platform. Revenue is generated through product sales, supply agreements, and licensing or partnership arrangements with governments and international health organizations. The 10-K filed 2026-02-26 (accession 000100069426000007) does not provide sufficient detail in the excerpts supplied to confirm specific revenue figures, segment breakdowns, geographic mix percentages, named competitors, or leadership tenure. Based solely on the available filing excerpts, further specifics on market position, customer concentration, capital structure, and founding history cannot be confirmed and are therefore omitted. The company is incorporated in the United States and files with the SEC as a well-known seasoned issuer as of the filing date.
Products & Services
Protein-based recombinant nanoparticle COVID-19 vaccine; proprietary vaccine technology platform.
Revenue Model
Product sales, government and multilateral supply agreements, and partnership or licensing arrangements for its COVID-19 vaccine and vaccine technology platform.
Customers & Markets
Governments and international health organizations purchasing COVID-19 vaccines; public health end market.
Financial Snapshot
Loading...
